Literature DB >> 22209744

Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States.

Hilmar Wisplinghoff1, Tobias Paulus, Marianne Lugenheim, Danuta Stefanik, Paul G Higgins, Michael B Edmond, Richard P Wenzel, Harald Seifert.   

Abstract

OBJECTIVES: To compare the clinical features and antimicrobial susceptibilities of the clinically most important Acinetobacter species Acinetobacter baumannii, Acinetobacter pittii (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis (formerly Acinetobacter genomic species 13TU).
METHODS: 295 Acinetobacter isolates collected prospectively from patients with bloodstream infections (BSI) in 52 US hospitals were identified to species level. Clinical and microbiological features were compared between species.
RESULTS: A. baumannii (63%) was the most prevalent species, followed by A. nosocomialis (21%), and A. pittii (8%). Intravascular catheters (15.3%) and the respiratory tract (12.9%) were the most frequent sources of BSI. A higher overall mortality was observed in patients with A. baumannii BSI than in patients with BSI caused by A. nosocomialis and A. pittii (36.9% vs. 16.4% and 13.0%, resp., p < 0.001). The most active antimicrobial agents as determined by broth microdilution were tigecycline (99.6% of isolates susceptible), colistin (99.3%), amikacin (98.5%), and imipenem (95.2%). 27 isolates (10.0%) were multi-drug resistant, all but one of these were A. baumannii.
CONCLUSIONS: About one third of Acinetobacter BSI in our study were caused by A. nosocomialis or A. pittii. Patients with A. baumannii BSI had a less favorable outcome.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209744     DOI: 10.1016/j.jinf.2011.12.008

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  67 in total

1.  KatG and KatE confer Acinetobacter resistance to hydrogen peroxide but sensitize bacteria to killing by phagocytic respiratory burst.

Authors:  Daqing Sun; Sara A Crowell; Christian M Harding; P Malaka De Silva; Alistair Harrison; Dinesh M Fernando; Kevin M Mason; Estevan Santana; Peter C Loewen; Ayush Kumar; Yusen Liu
Journal:  Life Sci       Date:  2016-02-06       Impact factor: 5.037

2.  A Prospective Study of Acinetobacter baumannii Complex Isolates and Colistin Susceptibility Monitoring by Mass Spectrometry of Microbial Membrane Glycolipids.

Authors:  Lisa M Leung; Christi L McElheny; Francesca M Gardner; Courtney E Chandler; Sarah L Bowler; Roberta T Mettus; Caressa N Spychala; Erin L Fowler; Belita N A Opene; Robert A Myers; David R Goodlett; Yohei Doi; Robert K Ernst
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

3.  Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital.

Authors:  Seung Yeob Lee; Jong Hee Shin; Kyung Hwa Park; Ju Hee Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang; Soo Hyun Kim
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

4.  Discrimination of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex species by Fourier transform infrared spectroscopy.

Authors:  C Sousa; L Silva; F Grosso; A Nemec; J Lopes; L Peixe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-22       Impact factor: 3.267

5.  Outer membrane Protein A plays a role in pathogenesis of Acinetobacter nosocomialis.

Authors:  Sang Woo Kim; Man Hwan Oh; So Hyun Jun; Hyejin Jeon; Seung Il Kim; Kwangho Kim; Yoo Chul Lee; Je Chul Lee
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

6.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

7.  Genomic and Biochemical Characterization of Acinetobacter Podophage Petty Reveals a Novel Lysis Mechanism and Tail-Associated Depolymerase Activity.

Authors:  A C Hernandez-Morales; L L Lessor; T L Wood; D Migl; E M Mijalis; J Cahill; W K Russell; R F Young; J J Gill
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

8.  AbaR-type genomic islands in non-baumannii Acinetobacter species isolates from South Korea.

Authors:  Dae Hun Kim; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

Review 9.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

10.  Use of Comparative Genomics To Characterize the Diversity of Acinetobacter baumannii Surveillance Isolates in a Health Care Institution.

Authors:  Lalena Wallace; Sean C Daugherty; Sushma Nagaraj; J Kristie Johnson; Anthony D Harris; David A Rasko
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.